As a leading company in the antibody development market, experts in Creative Biolabs possess enriched experience in bispecific antibody (BsAb) development. We can offer many different technical platforms and BsAb formats for customers and focus on ideal BsAbs design and development that meet all requirements of the customers.
As its name indicates, bispecific antibodies contain two different antigen-binding sites. They are a type of reconstructive molecules that can recognize two different epitopes. Generally, BsAb can be divided into two major classes, those bearing an Fc region and those lacking an Fc region, the latter normally being smaller than the IgG and IgG-like bispecific molecules comprising an Fc. BsAbs were initially described in the 1960s, and the first monoclonal BsAbs were produced in the 1980s by hybridoma technology. The number of papers regarding BsAbs has greatly increased in the last ten years, especially due to their therapeutic use. Remarkably, the approval of the two BsAbs, Anti-CD3 x Anti-EPCAM IgG-like BsAb and Anti-CD3 x Anti-CD19 BiTE, has become a significant milestone in the development of BsAbs.
Fig.1 Schematic overview of the different strategies used to generate bispecific antibodies (bsAbs) derived from the antigen binding sites of two different antibodies.
BsAbs are artificially designed molecules that enable simultaneously identify two or more different antigens. Here, Creative Biolabs is proud of introducing the following one-stop, customized antibody development services, involving the design, engineering, manufacturing, and analysis of BsAb.
At the beginning of BsAb development, Creative Biolabs can offer customized BsAb design and experimental workflows either for fundamental research or clinical trials. More than that, we are able to provide a full series of BsAbs to meet every client’s needs.
During the past decades, Creative Biolabs has developed its own antibody engineering platform to support novel and functional BsAbs for various therapeutic applications. We can provide BsAb engineering services to adjust their properties including size, valency, flexibility, half-life, biodistribution, etc., or other specific requirements.
With the rapid pace of recombinant protein technology, BsAbs are increasingly considered as emerging therapeutic proteins. Creative Biolabs has established three strategies to develop BsAbs and achieve large-scale generation for customers as follows.
Quality assessment, characteristic analysis, and preclinical research are necessary for different stages of BsAb development. Equipped with advanced facilities, Creative Biolabs has strong capability to assist customers in the BsAb analysis of basic and clinical research for further developing.
This dual specificity opens up a broad range of applications, including directing T cells to tumor cells, blocking two different signaling pathways meanwhile, dual targeting of diverse disease mediators, as well as delivering effective loads to targeted sites. There are more than 100 BsAb formats exist and at least 30 BsAb molecules currently in clinical pipeline/development, mainly for oncology, autoimmune and chronic inflammatory indications. They have been reportedly applied in a number of fields as summarized.
a. Guiding effector cells to disease cells;
b. Targeting disease pathway;
c. Blocking cytokines/receptors;
d. Forced protein associations
e. As a delivery vehicle;
Creative Biolabs has years of experience to offer innovative and sophisticated bispecific antibody (BsAb) development services tailored to customers’ exact needs. Please don’t hesitate to contact us or reach us by e-mail or phone with your particular needs.
1. Kontermann, R.E.; Brinkmann, U. Bispecific antibodies. Drug Discov Today. 2015, 20(7): 838-847.